$0.84 EPS Expected for Sanofi (SNY)

April 16, 2018 - By Henry Gaston

Sanofi (NYSE:SNY) Logo

Analysts expect Sanofi (NYSE:SNY) to report $0.84 EPS on April, 27.They anticipate $0.08 EPS change or 10.53 % from last quarter’s $0.76 EPS. SNY’s profit would be $2.09B giving it 12.13 P/E if the $0.84 EPS is correct. After having $0.62 EPS previously, Sanofi’s analysts see 35.48 % EPS growth. The stock increased 0.47% or $0.19 during the last trading session, reaching $40.75. About 778,103 shares traded. Sanofi (NYSE:SNY) has declined 13.31% since April 17, 2017 and is downtrending. It has underperformed by 24.86% the S&P500.

Sanofi (NYSE:SNY) Ratings Coverage

Among 5 analysts covering Sanofi American Depositary Shares (Each repstg one-half of one ordinary share) (NYSE:SNY), 0 have Buy rating, 2 Sell and 3 Hold. Therefore 0 are positive. Sanofi American Depositary Shares (Each repstg one-half of one ordinary share) had 6 analyst reports since November 15, 2017 according to SRatingsIntel. The stock of Sanofi (NYSE:SNY) earned “Equal-Weight” rating by Barclays Capital on Wednesday, November 15. The firm has “Underweight” rating by Morgan Stanley given on Friday, December 1. The rating was maintained by Cowen & Co on Monday, December 18 with “Hold”. Bank of America downgraded Sanofi (NYSE:SNY) on Wednesday, December 6 to “Hold” rating. The firm earned “Hold” rating on Thursday, February 8 by Bernstein. The firm has “Underweight” rating given on Tuesday, January 23 by Barclays Capital.

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of $101.61 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines. It has a 9.96 P/E ratio. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Sanofi (NYSE:SNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.